Study Summary
The aim of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines CAR T cells and IgT cells to treat sarcoma.
Want to learn more about this trial?
Request More InfoInterventions
Sarcoma-specific CAR-T cellsBIOLOGICAL
1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Shenzhen Geno-immune Medical Institute | Shenzhen | Guangdong | China |